Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec and Temozolomide in advanced melanoma
NCT00667953Phase 2Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2003
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in melanoma, sponsored by Abramson Cancer Center. Started Jan 2003; status: terminated.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00667953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667953.